Sandoz settles pricing suits with Florida, California

Novartis' ($NVS) generics unit Sandoz has agreed to pay $150 million to settle pricing-fraud lawsuits filed by the states of Florida and California. It's the latest settlement in ongoing probes of average wholesale pricing in the pharma industry. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.